deltatrials
Completed PHASE4 NCT00006864

Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin

Sponsor: Case Comprehensive Cancer Center

Conditions Kidney Cancer
Interventions aldesleukin
Updated 6 times since 2017 Last updated: Jan 8, 2014 Started: Jul 31, 2000 Primary completion: Jul 31, 2007 Completion: Jul 31, 2007

This PHASE4 trial investigates Kidney Cancer and is currently completed. Case Comprehensive Cancer Center leads this study, which shows 6 recorded versions since 2000 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE4

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE4

    First recorded

Jul 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Case Comprehensive Cancer Center
  • Chiron Corporation
  • National Cancer Institute (NCI)
Data source: Case Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Cleveland, United States
  • • Torrington, United States